The Emerging Role of Lipoprotein(a) in Cardiovascular Risk Among Diabetes Patients

Diabetes mellitus remains one of the most formidable chronic metabolic disorders worldwide, affecting over 537 million adults according to the International Diabetes Federation. The relationship between diabetes and cardiovascular disease (CVD) is well established, with individuals living with diabetes facing a two- to four-fold increased risk of developing cardiovascular complications compared to their non-diabetic counterparts. Despite significant advances in glycemic control, blood pressure management, and lipid-lowering therapies, patients with diabetes continue to experience disproportionately high rates of myocardial infarction, stroke, and cardiovascular mortality. This persistent risk gap suggests that traditional risk factors alone cannot fully explain or predict cardiovascular vulnerability in this population.

In the search for novel biomarkers that can refine risk stratification and guide therapeutic decision-making, lipoprotein(a) [Lp(a)] has attracted considerable attention from the cardiovascular and endocrine research communities. This distinctive lipoprotein particle, first described by Berg in 1963, possesses unique structural features that confer both atherogenic and thrombogenic potential. The growing body of evidence linking elevated Lp(a) levels to adverse cardiovascular outcomes, particularly in high-risk populations such as those with diabetes, has prompted calls for broader clinical adoption of Lp(a) testing. This article provides a comprehensive examination of circulating Lp(a) as a cardiovascular risk biomarker in patients with diabetes, integrating current understanding of its molecular biology, epidemiological associations, clinical measurement considerations, and emerging therapeutic strategies.

Molecular Architecture and Genetic Foundations of Lipoprotein(a)

Lipoprotein(a) is a complex lipoprotein particle that shares considerable structural homology with low-density lipoprotein (LDL) while possessing distinctive features that underlie its unique pathogenic properties. Each Lp(a) particle consists of a central core of hydrophobic lipids, including cholesteryl esters and triglycerides, surrounded by a phospholipid monolayer similar to that found in LDL. The key distinguishing feature of Lp(a) is the presence of apolipoprotein(a) [apo(a)], a large, highly glycosylated protein that is covalently attached to apolipoprotein B-100 (apoB-100) through a single disulfide bond. This covalent linkage occurs at the level of kringle IV type 9 domain of apo(a) and the carboxyl-terminal region of apoB-100, creating a particle that is both structurally unique and functionally versatile.

The apo(a) component exhibits remarkable size heterogeneity, ranging from approximately 300 kDa to over 800 kDa, depending on the number of kringle IV type 2 (KIV-2) repeats encoded by the LPA gene. Kringle domains are triple-looped protein structures stabilized by three internal disulfide bonds that were first identified in plasminogen and subsequently found to mediate protein-protein interactions. The number of KIV-2 repeats varies inversely with Lp(a) plasma concentration, meaning that individuals with fewer repeats produce smaller apo(a) isoforms that are synthesized and secreted more efficiently by the liver, resulting in higher circulating Lp(a) levels. This inverse relationship between isoform size and plasma concentration is a hallmark of Lp(a) biology and explains much of the inter-individual variability observed in clinical practice.

Genetic Determinants and Heritability Patterns

The plasma concentration of Lp(a) is among the most heritable quantitative traits in human biology, with heritability estimates consistently exceeding 90% across diverse populations. The LPA gene, located on chromosome 6q26-27, contains a remarkably polymorphic region encompassing the KIV-2 repeat sequences. More than 30 single-nucleotide polymorphisms (SNPs) within the LPA gene have been robustly associated with Lp(a) concentrations through large-scale genome-wide association studies. Among these, rs10455872 and rs3798220 are the most extensively characterized variants, each independently associated with elevated Lp(a) levels and increased cardiovascular risk.

Population differences in Lp(a) distribution are substantial and genetically determined. Individuals of African descent typically have Lp(a) levels two- to three-fold higher than those of European or Asian ancestry, with median concentrations around 30-40 mg/dL compared to 10-15 mg/dL in European populations. These differences reflect variations in the frequency of small apo(a) isoforms and specific risk-associated SNPs across ancestral groups. Importantly, Mendelian randomization studies have provided compelling evidence that genetically elevated Lp(a) is causally associated with increased risk of coronary heart disease, ischemic stroke, and calcific aortic valve stenosis, establishing Lp(a) as a lifelong, genetically-determined exposure that contributes to atherosclerotic cardiovascular disease independently of LDL cholesterol and other traditional risk factors.

Pathophysiological Mechanisms Linking Lp(a) to Cardiovascular Disease

Understanding the multiple mechanisms through which Lp(a) promotes cardiovascular pathology is essential for appreciating its particular relevance in diabetes patients, who already exhibit a heightened pro-inflammatory and pro-thrombotic state. Lp(a) acts through at least three interconnected pathways: direct atherogenesis, pro-inflammatory signaling, and impairment of normal fibrinolytic function. These mechanisms operate synergistically with the metabolic disturbances characteristic of diabetes to amplify cardiovascular risk beyond what would be predicted by traditional risk factor assessment alone.

Atherogenic Mechanisms at the Molecular Level

Like LDL particles, Lp(a) can cross the endothelial barrier and enter the arterial intima, where they become trapped through interactions with proteoglycans in the subendothelial matrix. However, Lp(a) exhibits enhanced binding affinity for proteoglycans compared to LDL due to the presence of the apo(a) moiety and its associated oxidized phospholipids. Once retained in the intima, Lp(a) particles undergo oxidative modification and are taken up by macrophages through scavenger receptors, including CD36 and SR-A, leading to foam cell formation and the initiation of atherosclerotic plaque development.

The oxidized phospholipids carried by Lp(a) are particularly important mediators of its atherogenic effects. These bioactive lipids activate endothelial cells, upregulating the expression of adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), which promote the recruitment of circulating monocytes into the arterial wall. Furthermore, oxidized phospholipids stimulate the release of pro-inflammatory cytokines from vascular cells and activate the unfolded protein response in endoplasmic reticulum, contributing to endothelial dysfunction and plaque instability. In diabetes patients, hyperglycemia and advanced glycation end-products (AGEs) independently activate many of these same pathways, creating a synergistic amplification of vascular inflammation and atherosclerosis progression.

Pro-Inflammatory and Immunomodulatory Effects

Beyond its direct atherogenic effects, Lp(a) functions as an acute phase reactant and modulator of inflammatory responses. The apo(a) component can bind to pro-inflammatory oxidized phospholipids and deliver them to cells in the vessel wall, where they activate inflammatory signaling cascades involving nuclear factor kappa-B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. This results in increased production of interleukin-6, interleukin-8, tumor necrosis factor-alpha, and monocyte chemoattractant protein-1 from vascular smooth muscle cells, endothelial cells, and infiltrating macrophages.

Lp(a) also interacts with components of the innate immune system. Studies have demonstrated that Lp(a) can bind to complement proteins and modulate complement activation, potentially influencing the inflammatory milieu within atherosclerotic plaques. Additionally, Lp(a) particles can be recognized by toll-like receptors on immune cells, further amplifying pro-inflammatory signaling. In the context of diabetes, where chronic low-grade inflammation is a hallmark feature characterized by elevated levels of C-reactive protein, interleukin-6, and other inflammatory markers, the additional inflammatory burden imposed by elevated Lp(a) may be particularly detrimental.

Thrombotic and Fibrinolytic Interference

The structural homology between apo(a) and plasminogen represents one of the most clinically relevant features of Lp(a) biology. Apo(a) contains multiple kringle domains that are highly similar to the kringle IV domain of plasminogen, allowing Lp(a) to compete with plasminogen for binding to fibrin, cell surfaces, and other plasminogen receptors. This competitive inhibition impairs the conversion of plasminogen to plasmin by tissue-type plasminogen activator, resulting in reduced fibrinolytic capacity and a relative pro-thrombotic state.

This anti-fibrinolytic effect has important clinical implications for diabetes patients, who already exhibit impaired fibrinolysis due to elevated plasminogen activator inhibitor-1 (PAI-1) levels associated with insulin resistance and hyperglycemia. The combination of high Lp(a) levels and diabetes-related fibrinolytic dysfunction creates a particularly unfavorable hemostatic balance that increases the risk of occlusive thrombus formation following atherosclerotic plaque rupture. Moreover, Lp(a) can directly promote platelet activation and aggregation through interactions with platelet receptors, further contributing to the thrombotic tendency.

Epidemiological Evidence Linking Lp(a) to Cardiovascular Risk in Diabetes

The relationship between Lp(a) and cardiovascular risk in diabetes patients has been extensively investigated, though early studies yielded somewhat inconsistent results. Some initial cross-sectional and small prospective studies suggested that Lp(a) levels might be lower in individuals with diabetes compared to those without, leading to uncertainty about the relevance of Lp(a) as a risk factor in this population. However, more recent large-scale prospective cohorts and meta-analyses with adequate sample sizes and longer follow-up periods have provided robust evidence that elevated Lp(a) is a significant predictor of cardiovascular events in diabetes patients, with effect sizes comparable to or exceeding those observed in non-diabetic populations.

Major Prospective Cohort Studies and Meta-Analyses

The Emerging Risk Factors Collaboration, a landmark pooling project that included data from over 126,000 participants across multiple prospective studies, provided some of the most compelling evidence for the association between Lp(a) and cardiovascular disease. This analysis demonstrated that Lp(a) levels above 50 mg/dL were associated with a hazard ratio of approximately 1.5 for coronary heart disease after adjustment for traditional risk factors, with no significant attenuation of the association in diabetes patients compared to non-diabetic individuals. The relationship was continuous and linear across the distribution of Lp(a) levels, with no evidence of a threshold effect.

A comprehensive systematic review and meta-analysis specifically examining the relationship between Lp(a) and cardiovascular outcomes in diabetes patients included 12 prospective studies with over 100,000 participants and more than 8,000 cardiovascular events. The pooled analysis found that each one-standard-deviation increase in log-transformed Lp(a) was associated with a 13% increased risk of coronary heart disease in individuals with diabetes (relative risk 1.13, 95% confidence interval 1.05-1.21), an effect size remarkably similar to that observed in non-diabetic participants. Importantly, this association remained significant after adjustment for LDL cholesterol, HbA1c, and other diabetes-related variables, supporting the independent predictive value of Lp(a) in this population.

Diabetes-Specific Risk Amplification

Several studies have suggested that the cardiovascular risk associated with elevated Lp(a) may be particularly pronounced in certain subgroups of diabetes patients. Patients with type 2 diabetes and Lp(a) levels exceeding 50 mg/dL appear to have approximately twice the risk of major adverse cardiovascular events compared to those with lower levels, independent of LDL cholesterol and glycemic control. The interaction between Lp(a) and diabetes may be especially relevant in patients with established cardiovascular disease, where elevated Lp(a) identifies individuals at particularly high risk for recurrent events despite optimal guideline-directed medical therapy.

Emerging evidence also suggests that the relationship between Lp(a) and cardiovascular risk in diabetes may vary by sex and ethnicity. Some studies have reported stronger associations in women with diabetes compared to men, though the biological basis for this sex-specific effect remains unclear. Additionally, the higher baseline Lp(a) levels observed in individuals of African ancestry raise questions about whether the same risk thresholds should be applied across different ethnic groups, an issue that warrants further investigation in diverse study populations.

Factors Complicating Lp(a) Interpretation in Diabetes

Several diabetes-specific factors can influence Lp(a) measurements and complicate their interpretation in clinical practice. Glycemic control appears to have a modest but variable effect on Lp(a) levels. Some studies have reported that insulin therapy and improvements in glycemic control reduce Lp(a) concentrations by 10-20%, while others have found no significant effect. The relationship may be influenced by the type of diabetes and the specific glucose-lowering medications used, with metformin and thiazolidinediones potentially having Lp(a)-lowering effects, while sulfonylureas may not.

Diabetic nephropathy represents another important confounder in the Lp(a)-cardiovascular risk relationship. As kidney function declines, Lp(a) catabolism is impaired, leading to progressive increases in Lp(a) levels that correlate with the severity of renal impairment. In patients with diabetic kidney disease, elevated Lp(a) may therefore reflect both genetic predisposition and acquired accumulation due to reduced clearance. This dual origin of elevated Lp(a) in the setting of nephropathy complicates risk assessment and highlights the need for careful interpretation of Lp(a) levels in patients with impaired renal function.

Insulin resistance itself may modulate Lp(a) metabolism through effects on hepatic apo(a) production and clearance. Some studies have suggested that the relationship between Lp(a) and cardiovascular risk is attenuated in the presence of marked insulin resistance, possibly due to the overwhelming influence of other metabolic abnormalities. However, this finding has not been consistently replicated, and current evidence supports the utility of Lp(a) measurement across the full spectrum of insulin resistance.

Clinical Measurement and Interpretation of Lp(a)

The clinical utility of Lp(a) as a cardiovascular risk biomarker depends critically on accurate, reproducible, and standardized measurement methods. Historically, the availability of multiple assay formats with different antibodies, calibrators, and reporting units has hindered the comparability of Lp(a) results across laboratories and clinical studies. Recent efforts by international organizations have sought to address these challenges and establish guidelines for harmonized Lp(a) testing that can support evidence-based clinical decision-making.

Assay Technologies and Standardization Efforts

Current methods for Lp(a) measurement include immunonephelometry, immunoturbidimetry, and enzyme-linked immunosorbent assays, each using antibodies directed against epitopes on the apo(a) component. A significant limitation of these immunoassays is that the number of KIV-2 repeats in apo(a) affects antibody binding, potentially leading to underestimation of Lp(a) levels in individuals with large apo(a) isoforms and overestimation in those with small isoforms. This isoform-dependent bias can introduce systematic errors that vary across patient populations and complicate risk stratification.

The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) has developed a reference material (IFCC SRM 2B) intended to serve as a primary calibrator for Lp(a) assays. The recommended unit of measurement is nmol/L, which reflects the molar concentration of Lp(a) particles and is less affected by apo(a) isoform size than mass-based units (mg/dL). Conversion factors between nmol/L and mg/dL vary depending on the assay and the isoform composition of the sample, but a commonly used approximation is that 1 nmol/L corresponds to approximately 0.4 mg/dL. The adoption of nmol/L as the preferred reporting unit represents an important step toward harmonizing Lp(a) measurements across different platforms and laboratories.

Risk Thresholds and Clinical Decision-Making

Population-based studies have established several risk thresholds for Lp(a) that can guide clinical interpretation. The European Atherosclerosis Society recommends considering Lp(a) levels above 50 mg/dL (approximately 125 nmol/L) as indicative of high cardiovascular risk. This threshold corresponds to approximately the 80th percentile in most European populations and identifies individuals with a substantially increased lifetime risk of cardiovascular events. The American Heart Association and American College of Cardiology have similarly endorsed Lp(a) measurement in selected high-risk populations, though they have not specified a single universal threshold, recognizing that risk may be continuous across the distribution of Lp(a) levels.

For diabetes patients specifically, some experts have proposed a lower threshold of 30 mg/dL (approximately 75 nmol/L) for defining elevated risk, based on evidence that the risk gradient associated with Lp(a) may be steeper in this population. However, this lower threshold has not been universally adopted, and current guidelines from major diabetes organizations do not provide specific Lp(a)-based risk cutoffs for diabetic patients. Clinicians should consider Lp(a) levels in the context of the patient's overall risk profile, including age, sex, duration of diabetes, glycemic control, blood pressure, smoking status, and the presence of other lipid abnormalities.

Current Guideline Recommendations for Lp(a) Testing

Major cardiovascular and lipid management guidelines now recommend Lp(a) measurement in specific clinical scenarios. The European Society of Cardiology and European Atherosclerosis Society guidelines suggest measuring Lp(a) at least once in all adults with premature cardiovascular disease, a strong family history of premature atherosclerosis, familial hypercholesterolemia, or recurrent cardiovascular events despite optimal lipid-lowering therapy. More recently, some expert panels have extended these recommendations to include patients with diabetes, particularly those with additional risk factors or evidence of subclinical atherosclerosis.

The American Diabetes Association's Standards of Medical Care in Diabetes acknowledge that Lp(a) may be a useful biomarker for cardiovascular risk assessment in selected patients with diabetes. The association recommends considering Lp(a) measurement in adults with diabetes who have a family history of premature cardiovascular disease, personal history of cardiovascular events, or when standard risk assessment suggests intermediate or high risk. However, routine universal screening for Lp(a) in all diabetes patients is not currently recommended, pending further evidence on the cost-effectiveness and clinical impact of such an approach.

Current and Emerging Therapeutic Strategies for Elevated Lp(a)

One of the most frustrating aspects of Lp(a) management has been the relative lack of effective pharmacologic interventions. Unlike LDL cholesterol, which can be substantially reduced with statins, ezetimibe, and PCSK9 inhibitors, Lp(a) has proven resistant to most conventional lipid-lowering therapies. However, the development of novel agents that specifically target Lp(a) production represents a major therapeutic advance that may transform the management of patients with elevated levels, including those with diabetes.

Response to Conventional Risk Factor Modification

Lifestyle interventions, including dietary modification, weight loss, and increased physical activity, have minimal effects on Lp(a) levels. Most studies report reductions of less than 10%, which are unlikely to meaningfully alter cardiovascular risk. This relative resistance to lifestyle modification reflects the strong genetic determination of Lp(a) levels and distinguishes Lp(a) from other lipid parameters that are more responsive to environmental factors.

Statins, the cornerstone of pharmacologic lipid management, do not lower Lp(a) and may actually increase levels by 10-20% in some patients, particularly those receiving high-intensity statin therapy. The mechanism underlying this statin-induced increase is not fully understood but may involve upregulation of LPA gene expression or reduced hepatic clearance of Lp(a) particles. Ezetimibe, a cholesterol absorption inhibitor, has similarly neutral effects on Lp(a). These observations highlight the importance of measuring Lp(a) in patients receiving statin therapy, as an elevated level in this setting signals residual risk that is not addressed by standard lipid-lowering treatment.

PCSK9 inhibitors (evolocumab and alirocumab) have emerged as the most effective currently available agents for reducing Lp(a), producing dose-dependent reductions of 20-30% when added to statin therapy. The clinical significance of this reduction has been supported by post-hoc analyses of the FOURIER and ODYSSEY OUTCOMES trials, which demonstrated that patients with higher baseline Lp(a) levels derived greater cardiovascular benefit from PCSK9 inhibition, and that the reduction in Lp(a) contributed independently to the observed risk reduction. For diabetes patients with elevated Lp(a) who require additional lipid lowering beyond statin therapy, PCSK9 inhibitors offer the dual benefit of reducing both LDL cholesterol and Lp(a).

Niacin (nicotinic acid) has historically been recognized as one of the few agents that can substantially reduce Lp(a), with typical reductions of 20-30% at therapeutic doses. However, niacin's utility is limited by a high incidence of bothersome side effects, including cutaneous flushing, pruritus, gastrointestinal discomfort, and hepatotoxicity. Moreover, large clinical outcome trials, including the HPS2-THRIVE study, failed to demonstrate cardiovascular benefit with niacin when added to intensive statin therapy, despite significant reductions in Lp(a) and other lipid parameters. This lack of outcome benefit, coupled with the side effect profile, has substantially diminished enthusiasm for niacin as a therapeutic option for Lp(a) reduction.

Targeted Therapies Under Development

The most exciting developments in Lp(a)-targeted therapy involve antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) molecules that directly inhibit hepatic production of apo(a). These agents represent a paradigm shift in the pharmacologic approach to Lp(a) elevation, moving from indirect and modest effects to potent and specific suppression of the primary source of Lp(a) production.

Pelacarsen (formerly TQJ230), an ASO that targets LPA mRNA in hepatocytes, has shown remarkable efficacy in clinical trials. In the phase 2 trial involving patients with established cardiovascular disease and elevated Lp(a) levels above 60 mg/dL, pelacarsen produced dose-dependent reductions in Lp(a) of up to 80% with weekly subcutaneous administration. The treatment was generally well tolerated, with injection site reactions and mild thrombocytopenia being the most notable adverse effects. Pelacarsen is currently being evaluated in the phase 3 Lp(a) HORIZON cardiovascular outcomes trial, which is enrolling patients with elevated Lp(a) levels and established cardiovascular disease to determine whether Lp(a) reduction translates into reduced cardiovascular events.

Olpasiran (AMG 890), an siRNA therapeutic that also targets LPA mRNA, has demonstrated similarly impressive Lp(a) reductions in early-phase trials. The phase 2 OCEAN(a)-DOSE trial tested multiple dosing regimens and found that olpasiran administered subcutaneously every 12 weeks produced sustained Lp(a) reductions exceeding 80% at the highest doses. The tolerability profile was favorable, with no serious adverse events attributed to the study drug. The phase 3 OCEAN(a)-OUTCOMES trial is now underway to evaluate the cardiovascular efficacy of olpasiran in patients with elevated Lp(a) and established atherosclerotic cardiovascular disease.

Several additional agents, including other ASOs and siRNAs targeting different regions of the LPA gene, as well as gene editing approaches using CRISPR-Cas9 technology, are in various stages of preclinical and clinical development. If the ongoing outcome trials demonstrate cardiovascular benefit, these agents could establish a new class of therapies specifically indicated for Lp(a) reduction, potentially benefiting millions of patients worldwide, including a substantial proportion of the diabetes population.

Clinical Implications and Practical Recommendations

The growing body of evidence supporting Lp(a) as an independent cardiovascular risk factor in diabetes patients has important implications for clinical practice. While widespread adoption of Lp(a) testing requires further data on cost-effectiveness and outcomes, several practical recommendations can guide clinicians in incorporating Lp(a) assessment into the routine cardiovascular risk evaluation of diabetes patients.

Measurement of Lp(a) should be considered in diabetes patients with a strong family history of premature cardiovascular disease, personal history of atherosclerotic cardiovascular disease, or when standard risk assessment indicates intermediate or high risk. A single measurement is generally sufficient, as Lp(a) levels remain relatively stable throughout adult life, with minimal variation related to age, dietary patterns, or medication use. The test can be performed on a non-fasting blood sample and should be reported in nmol/L using an isoform-independent assay when possible.

When elevated Lp(a) is identified, clinicians should interpret the result in the context of the patient's overall cardiovascular risk profile. For diabetes patients with Lp(a) levels above 50 mg/dL (125 nmol/L), aggressive management of other modifiable risk factors is warranted, including intensive LDL cholesterol lowering with statins and ezetimibe, optimal blood pressure control, smoking cessation, and careful glycemic management. Consideration should be given to adding a PCSK9 inhibitor, which offers the dual benefit of LDL cholesterol and Lp(a) reduction, particularly in patients with established cardiovascular disease or those at very high risk.

Patients should be counseled about the genetic nature of Lp(a) elevation and the implications for family members. Testing of first-degree relatives should be considered, particularly in families with a strong history of premature cardiovascular disease. For patients with persistently elevated Lp(a) despite optimal management of other risk factors, referral to a lipid specialist or cardiovascular prevention clinic may be appropriate, especially as newer targeted therapies become available through clinical trials or eventual regulatory approval.

Future Research Directions and Unanswered Questions

Despite substantial progress in understanding Lp(a) biology and its clinical significance, several important questions remain unanswered. The interaction between Lp(a) and glycemic control deserves further investigation, particularly the question of whether intensive diabetes management can attenuate the cardiovascular risk associated with elevated Lp(a). The relationship between Lp(a) and specific diabetes-related complications, including diabetic kidney disease, peripheral artery disease, and heart failure with preserved ejection fraction, requires dedicated study in adequately powered prospective cohorts.

The optimal threshold for intervention in diabetes patients, accounting for the modifying effects of diabetes duration, glycemic control, and the presence of complications, must be refined through additional research. The cost-effectiveness of routine Lp(a) screening in diabetes clinics, including the downstream costs of confirmatory testing, specialist referrals, and potential therapies, needs to be evaluated across different healthcare systems and populations. Furthermore, widespread adoption of Lp(a) testing will require continued efforts to standardize assays, educate clinicians about the interpretation of results, and develop evidence-based algorithms for clinical decision-making.

The results of ongoing cardiovascular outcome trials with pelacarsen, olpasiran, and other targeted therapies are eagerly anticipated and will provide definitive evidence regarding the clinical benefits of Lp(a) reduction. If these trials demonstrate positive results, they will establish Lp(a) as not only a risk biomarker but also a therapeutic target, ushering in a new era of personalized cardiovascular prevention for patients with diabetes and other high-risk conditions.

Conclusion

Circulating lipoprotein(a) represents an independent, genetically determined cardiovascular risk factor that retains and potentially amplifies its predictive value in patients with diabetes mellitus. Its unique structural features, combining the atherogenic potential of LDL-like particles with pro-inflammatory and anti-fibrinolytic properties, make it particularly relevant in the context of the metabolic disturbances characteristic of diabetes. The measurement of Lp(a) can enhance cardiovascular risk stratification beyond traditional risk factors and guide therapeutic decision-making in this high-risk population.

While current pharmacologic options for Lp(a) reduction remain limited, the emergence of targeted RNA-based therapies that potently and specifically suppress hepatic apo(a) production offers unprecedented opportunities for risk modification. The results of ongoing cardiovascular outcome trials will determine whether these novel agents can reduce cardiovascular events and potentially transform the clinical approach to Lp(a) management. In the meantime, clinicians caring for patients with diabetes should incorporate Lp(a) assessment into their routine cardiovascular evaluation, particularly in individuals with a strong family history of premature atherosclerotic disease, personal history of cardiovascular events, or borderline risk profiles where additional risk discrimination could guide management decisions. As the evidence base continues to evolve, Lp(a) testing is likely to become an increasingly important component of comprehensive cardiovascular risk assessment and personalized prevention strategies in diabetes care.

For further reading on this topic, refer to the European Atherosclerosis Society consensus statement on Lp(a), the meta-analysis of Lp(a) and cardiovascular risk in diabetes, the American College of Cardiology review of emerging Lp(a)-lowering therapies, and the Diabetes Care perspective on Lp(a) in diabetes management.